TNFSF9 and neoplasm: Here, we report here that assessments of both in vitro cytolysis of EGFRvIII target tumor cells as well as improved survival in an EGFRvIII positive intracranial human glioblastoma xenograft mouse model provide encouraging data that shows ‘third generation’ EGFRvIII-specific CAR T-cells, cocultured with EGFRvIII-specific aAPCs that additionally express CD32, CD80, and CD137L (4-1BBL) co-stimulatory molecules presents itself to be an effective strategy for preparation of EGFRvIII directed CAR therapy for human glioma.